anti-doping comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-07-01. Numbers and descriptions here follow the published literature rather than marketing material.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
A characterization of these fibers was given, as well as hypotheses for their growth in a nitrogen atmosphere at low pressures. In 1981, a group of Soviet scientists published the results of chemical and structural characterization of carbon nanoparticles produced by a thermocatalytic disproportionation of carbon monoxide. Using TEM images and XRD patterns, the authors suggested that their "carbon multi-layer tubular crystals" were formed by rolling graphene layers into cylinders. They speculated that via this rolling, many different arrangements of graphene hexagonal nets are possible. They suggested two such possible arrangements: a circular arrangement (armchair nanotube); and a spiral, helical arrangement (chiral tube). In 1987, Howard G. Tennent of Hyperion Catalysis was issued a U.S. patent for the production of "cylindrical discrete carbon fibrils" with a "constant diameter between about 3.5 and about 70 nanometers..., length 102 times the diameter, and an outer region of multiple essentially continuous layers of ordered carbon atoms and a distinct inner core...." Helping to create the initial excitement associated with carbon nanotubes were Iijima's 1991 discovery of multi-walled carbon nanotubes in the insoluble material of arc-burned graphite rods; and Mintmire, Dunlap, and White's independent prediction that if single-walled carbon nanotubes could be made, they would exhibit remarkable conducting properties. Nanotube research accelerated greatly following the independent discoveries by Iijima and Ichihashi at NEC and Bethune et al.
The cyclol hypothesis is the now discredited first structural model of a folded, globular protein, formulated in the 1930s. It was based on the cyclol reaction of peptide bonds proposed by physicist Charles Frank in 1936, in which two peptide groups are chemically crosslinked. These crosslinks are covalent analogs of the non-covalent hydrogen bonds between peptide groups and have been observed in rare cases, such as the ergopeptides. Based on this reaction, mathematician Dorothy Wrinch hypothesized in a series of five papers in the late 1930s a structural model of globular proteins. She postulated that, under some conditions, amino acids will spontaneously make the maximum possible number of cyclol crosslinks, resulting in cyclol molecules and cyclol fabrics. She further proposed that globular proteins have a tertiary structure corresponding to Platonic solids and semiregular polyhedra formed of cyclol fabrics with no free edges. In contrast to the cyclol reaction itself, these hypothetical molecules, fabrics and polyhedra have not been observed experimentally. The model has several consequences that render it energetically implausible, such as steric clashes between the protein sidechains. In response to such criticisms J. D. Bernal proposed that hydrophobic interactions are chiefly responsible for protein folding, which was indeed borne out.
He named this the "asteroid hypothesis" as an astronomical analogy: just as there is an asteroid belt instead of a single planet between Mars and Jupiter, so the place below yttrium was thought to be occupied by all the lanthanides instead of just one element.
=== Canada and United States === In the first decade of the 21st century, farmers in Canada and the United States began cultivating goji on a commercial scale to meet potential markets for fresh berries, juice, and processed products.
=== Medications === Oral medications like Glipizide that stimulate the pancreas, promoting insulin release (or in some cases, reduce glucose production), are less and less used in cats, and these drugs may be completely ineffective if the pancreas is not working. These drugs have also been shown in some studies to damage the pancreas further or to cause liver damage. Some owners are reluctant to switch from pills to insulin injections, but the fear is unjustified; the difference in cost and convenience is minor (most cats are easier to inject than to pill), and injections are more effective at treating the disease. Bexagliflozin (Bexacat) was approved for medical use in the United States in December 2022. It is the first sodium-glucose cotransporter 2 (SGLT2) inhibitor new animal drug approved by the US Food and Drug Administration (FDA) in any animal species. Velagliflozin (Senvelgo), another SGLT2 inhibitor, was approved for medical use in the United States in August 2023 by the FDA. SGLT2 inhibitors are not insulin, nor do they help a diabetic cat's cells use glucose for energy. SGLT2 inhibitors lowers blood glucose levels by excreting glucose through the kidneys. Both medications are prescription only and are given orally (by mouth) once daily. Cats that have been previously treated with long-term insulin therapy, are currently on long-term insulin therapy, or has other underlying health conditions should not take these medications.
Sources: en.wikipedia.org
== History == Click Chemistry was first fully described by K. Barry Sharpless, Hartmuth C. Kolb, and M. G. Finn of The Scripps Research Institute in 2001. The paper argued that synthetic chemistry could emulate the way nature constructs complex molecules, using efficient reactions to join together simple, non-toxic building blocks. Many perspectives have been offered on the concepts or principles of Click Chemistry. Some of these attributes include the quest for selectivity and ease of implementation, which of course, is a goal for many or most chemical reactions. Click Chemistry was founded on the recognition that most compounds in biology are "stitched together" by formation of C-heteroatom bonds (heteroatom = N, O, S). Few major classes of structurally complex organic compounds have more than six contiguous C-C bonds (except aryl derivatives). C-heteroatom bond forming reactions are often highly favorable and thus these bonds are strong. Of these C-heteroatom bond forming reactions, a few are particularly easy to implement. Sharpless et al. recommended a focus on certain cycloadditions, nucleophilic substitutions involving strained substrates, formation of ureas and ethers, and additions of heteroatoms to C=C bonds. Not mentioned in this landmark review was the Huisgen 1,3-dipolar cycloaddition, possibly because it was slow. The year after publication of Sharpless's review, Tornøe, Christensen, and Meldal at the Carlsberg Laboratory, Denmark described the copper-catalyzed addition of azides to alkynes, with no mention of Sharpless et al. nor of Click Chemistry.
Many birds actively defend a territory from others of the same species during the breeding season; maintenance of territories protects the food source for their chicks. Species that are unable to defend feeding territories, such as seabirds and swifts, often breed in colonies instead; this is thought to offer protection from predators. Colonial breeders defend small nesting sites, and competition between and within species for nesting sites can be intense. All birds lay amniotic eggs with hard shells made mostly of calcium carbonate. Hole and burrow nesting species tend to lay white or pale eggs, while open nesters lay camouflaged eggs. There are many exceptions to this pattern, however; the ground-nesting nightjars have pale eggs, and camouflage is instead provided by their plumage. Species that are victims of brood parasites have varying egg colours to improve the chances of spotting a parasite's egg, which forces female parasites to match their eggs to those of their hosts.
== Personal life == Beginning in 2014, Ayyadurai was romantically connected with actress Fran Drescher. On September 7, 2014, Ayyadurai and Drescher participated in a ceremony at Drescher's beach house. Both tweeted that they had gotten married, and the event was widely reported as such. Ayyadurai later said it was not "a formal wedding or marriage", but a celebration of their "friendship in a spiritual ceremony with close friends and her family". The couple split up in September 2016.
=== United Kingdom === A study in 2004 by the Independent Inquiry into Drug Testing at Work found that attempts by employers to force employees to take drug tests could potentially be challenged as a violation of privacy under the Human Rights Act 1998 and Article 8 of the European Convention of Human Rights. However, this does not apply to industries where drug testing is a matter of personal and public safety or security rather than productivity.
== Criticism == Numerous critiques have been made regarding the use of impact factors, both in terms of their statistical validity and also of their implications for how science is carried out and assessed. A 2007 study noted that the most fundamental flaw is that impact factors present the mean of data that are not normally distributed, and suggested that it would be more appropriate to present the median of these data. There is also a more general debate on the validity of the impact factor as a measure of journal importance and the effect of policies that editors may adopt to boost their impact factor (perhaps to the detriment of readers and writers). Other criticism focuses on the effect of the impact factor on the behavior of scholars, editors and other stakeholders. Criticism of impact factors also extends to its impact on researcher behavior. While the emphasis on high-impact journals may lead to strategic publishing practices that prioritize journal prestige over the quality and relevance of research, it's important to acknowledge the "privilege paradox". Younger researchers, particularly those from under-represented regions, often lack the established reputation or networks to secure recognition outside of these metrics. This can lead to a narrow focus on publishing in top-tier journals, potentially compromising the diversity of research topics and methodologies. Further criticisms argue that emphasis on impact factor results from the negative influence of neoliberal politics on academia.
Sources: en.wikipedia.org
=== Miscellaneous === Galactogogues such as the peripherally selective D2 receptor antagonist and prolactin releaser domperidone can be used to induce lactation in transgender women who wish to breastfeed. An extended period of combined estrogen and progestogen therapy is necessary to mature the lobuloalveolar tissue of the breasts before this can be successful. There are several published reports of lactation and/or breastfeeding in transgender women. The World Professional Association for Transgender Health (WPATH) Standards of Care for the Health of Transgender and Gender Diverse People Version 8 (SOC8), released in September 2022, recommends against therapeutic strategies including supraphysiological estradiol levels (>200 pg/mL), use of progesterone (including rectal progesterone), use of bicalutamide, and monitoring of the ratio of estrone to estradiol. This is due to lack of data to support these approaches in transfeminine people as well as potential risks. The WPATH SOC8 also recommends against the use of 5α-reductase inhibitors such as finasteride in transfeminine people.
The largest concentration of Southern Rhodesian troops in the Italian Campaign of 1943–45 was the group of about 1,400, mainly from the Southern Rhodesian Reconnaissance Regiment, spread across the South African 6th Armoured Division. The 11th South African Armoured Brigade, one of the 6th Division's two main components, was made up of Prince Alfred's Guard, the Pretoria Regiment (Princess Alice's Own) and the Special Service Battalion, each of which had a Rhodesian squadron of Sherman tanks. The other, the 12th South African Motorised Brigade, comprised infantry—the Witwatersrand Rifles, the Natal Carbineers and the Cape Town Highlanders, the last of which had a large Rhodesian contingent. There were also two Rhodesian artillery batteries—the original Rhodesian Anti-Tank Battery and a newer unit of Rhodesian field gunners. After a year's training in Egypt, the division sailed to Italy in April 1944, landing towards the end of the month at Taranto. No. 237 Squadron, now flying Spitfires, rebased to Corsica the same month to operate over Italy and southern France. The 6th Division moved north-west from Taranto to take its place as part of the Eighth Army alongside the US Fifth Army. It took part in the fourth and final Allied assault of the Battle of Monte Cassino in the second and third weeks of May 1944, helping to force the Germans out, and thereafter advanced north-west up the Liri valley to join the Allied forces at Anzio and advance onwards to Rome.
== Mechanism of toxicity == Once azinphos-methyl is absorbed it can cause neurotoxic effects, like other organophosphate insecticides. At high concentrations AzM itself can be toxic because it can function as an acetylcholinesterase (AChE) inhibitor. But its toxicity is mainly due to the bioactivation by a cytochrome P450 (CYP450)-mediated desulfuration to its phosphate triester or oxon(gutoxon) (see figure 2). Gutoxon can react with a serine hydroxyl group at the active site of the AChE. The active site is then blocked and AChE is inactivated. Under normal circumstances acetylcholinesterase rapidly and efficiently degrades the neurotransmitter acetylcholine (ACh) and thereby terminates the biological activity of acetylcholine. Inhibition of AChE results in an immediate accumulation of free unbound ACh at the ending of all cholinergic nerves, which leads to overstimulation of the nervous system.
According to Democracy Now!, "[r]esearchers did not obtain signed consent forms, and medical personnel said Pfizer did not tell parents their children were getting the experimental drug." The lawsuits also accused Pfizer of using the outbreak to perform unapproved human testing, as well as allegedly under-dosing a control group being treated with traditional antibiotics in order to skew the results of the trial in favor of Trovan. Nigerian medical personnel as well as at least one Pfizer physician said the trial was conducted without regulatory approval. In 2007, Pfizer published a Statement of Defense letter, claiming that Trozan was safely tested in five thousand patients prior to the Nigerian children clinical trial, and mortality in the patients treated by Pfizer was lower than that observed historically in African meningitis epidemics. They claim that the effects suffered by the victims were due to meningitis and not Trovan. Pfizer states that its actions did not violate any law, as there was no law in Nigeria that requires ethical committee approval prior to conducting a clinical trial. However, the drug was never tested in children before. Pfizer claims that no unusual side effects, unrelated to meningitis, were observed after four weeks in the Nigerian children clinical study, though an investigation by The Washington Post revealed that one of the children continued to have the drug administered to them until their death despite their condition worsening, which violated ethical guidelines.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.